Semaglutide and alcohol

What the labels say, which is nothing

Both capture files were searched for the word. In the WEGOVY label every hit is “nonalcoholic steatohepatitis”, the old name for the liver condition in its third approved use. In the OZEMPIC label the hits are those plus “alcohol swab”, in the instructions for cleaning your skin before an injection. Neither label contains a sentence about drinking.^1,2

That is a finding rather than an oversight to work around. A label lists what was studied and what prescribers must be told; an absence there means the question was not answered in the approval documents, not that the answer is yes and not that it is no.

What they do say that touches it

Two labeled facts sit close enough to matter. The first is blood sugar. Semaglutide on its own is not a common cause of hypoglycemia, but both labels carry a warning about it when the drug is combined with insulin or with a medicine that makes the body release insulin, and both tell prescribers to consider lowering those doses. Alcohol is a known complication in that territory, which is a conversation to have with the person managing those medicines.^1,2 The Ozempic side-effect guide distinguishes common trial reactions from the label’s serious warnings.

The second is fluid, and the label puts it plainly:

The events in that sentence are postmarketing reports of acute kidney injury. Anything that adds to fluid loss during the weeks when vomiting and diarrhea are most likely is worth knowing about, and the diarrhea page has the rates and the timing.

There is a third, and it applies to one group only: WEGOVY’s third approved use is a liver condition. Anyone taking it for that has a reason to ask about alcohol that has nothing to do with the drug interaction question, and their prescriber is the one to ask.¹

The research runs the other way

The published work on semaglutide and alcohol is not about whether you can drink on it. It asks whether the drug reduces drinking, and in 2026 a phase 2 randomized, double-blind trial in the American Journal of Psychiatry tested that directly. Fifty treatment-seeking adults with moderate to severe alcohol use disorder took oral semaglutide, 3 mg a day for four weeks then 7 mg a day for four weeks, or placebo.³

The primary outcome was laboratory-measured craving when participants were shown alcohol cues, at week 6. It did not separate from placebo, and neither did drinks per day. What did reach significance were secondary outcomes: fewer heavy drinking days, fewer drinks per drinking day, less craving as reported in daily life, fewer alcohol-related consequences, and more participants dropping at least one level on a risk-drinking scale.³

So if you have read that semaglutide cuts drinking, this is where it comes from, and the honest version includes the endpoint it missed.

What nobody has measured

The question this page is named for. No document held here measures what drinking does to the side effects of semaglutide taken for weight, or whether it changes how much weight comes off. The labels do not address it and the trial above was asking something else. That gap is where the confident answers on the internet come from, and it is the reason there is not one here.

Questions